The Janus kinase 2 (JAK2V617F) mutation is the main molecular marker of the Philadelphia-negative chronic myeloproliferative neoplasms (MPN), responsible for 95% of polycythaemia; 50% of thrombocythemia vera; and myelofibrosis cases [2]. Here, JAK2 is linked to myeloproliferative disorder.